Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Monotropitoside, also known as gaultherin, is a natural salicylate glycoside found in various plant species, including *Gaultheria yunnanensis* and *Filipendula ulmaria* (meadowsweet). It acts as a prodrug that is metabolically converted into salicylate, the active component responsible for its analgesic and anti-inflammatory effects. Preclinical studies have demonstrated its efficacy in animal models of rheumatoid arthritis, pain, and swelling, showing a potency comparable to aspirin but without the associated gastric ulcerogenic side effects. While it is a significant component of certain herbal remedies and has been investigated for its potential as a safer alternative to traditional non-steroidal anti-inflammatory drugs (NSAIDs), it remains primarily a research compound and is not currently marketed as a standalone pharmaceutical product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on monotropitoside.